With a commitment to advancing new drug development for liver and gastrointestinal (GI) diseases, Ace Therapeutics proudly announces the launch of its custom disease model development services, which come with a complete range of research services from target discovery to predictive efficacy testing. This strategic addition to Ace Therapeutics’ portfolio not only enhances its service offerings but also reinforces its role as a pivotal partner in the global effort to combat GI and liver diseases.
Custom disease models for gastrointestinal and hepatology research are crucial for understanding diseases related to the digestive system and liver, and they can be used for studying disease mechanisms, testing new treatments, and identifying potential drug targets. To develop robust disease models, several key steps and considerations should be included. For example, the models need to mimic human disease conditions and pathophysiology accurately and can be scaled for use in high-throughput screening. Therefore, realizing the complexity and challenges in developing disease models, Ace Therapeutics provides custom gastroenterology and hepatology models for global researchers engaged in GI and liver disease studies.
The custom model development services, focal to Ace Therapeutics’ expansion strategy, offer researchers and pharmaceutical companies the tools for subsequent experiments including compound screening and in-depth molecular efficacy analysis. Covering a broad spectrum of disease models such as gastroesophageal reflux disease (GERD) models and bile accumulation disease models, Ace Therapeutics can develop ideal models according to clients’ requirements. After being rigorously validated, these models will play a vital role in studying liver diseases and GI at a preclinical stage, thereby accelerating the path toward effective treatments and potential cures.
In addition to disease model development services, Ace Therapeutics also provides comprehensive drug development services from target identification and validation to preclinical testing. Based on its gastrointestinal and hepatic disease drug development platforms, Ace Therapeutics can achieve compound synthesis, protein expression and purification, pharmacodynamic research, and toxicology study.
As a preclinical service provider, Ace Therapeutics is dedicated to providing innovative solutions and services to empower gastroenterology and hepatology research. With a robust portfolio of services and a relentless commitment to quality and collaboration, Ace Therapeutics continues to push the boundaries of pharmaceutical research, aiming to transform the landscape of hepatology and GI.
